Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

This study is a pregnancy registry — not a treatment trial — that tracks the health outcomes of pregnant women who were exposed to relugolix (a hormone therapy used for conditions like uterine fibroids or prostate cancer) during pregnancy, and their babies. The goal is to understand whether this medication poses any risks during pregnancy. **You may be eligible if...** - You are a woman of any age who is currently or was recently pregnant - You were exposed to at least one dose of a relugolix-containing medication at any point during your pregnancy (Cohort 1), OR - You have a condition for which relugolix may be prescribed but you did not take it during pregnancy (Cohort 2) - You consent to having your healthcare provider share data with the registry **You may NOT be eligible if...** - Your pregnancy outcome already happened before you first contacted the study - You were exposed to medications known to cause birth defects during the pregnancy - You are lost to follow-up and cannot be contacted for updates Talk to your doctor to see if this trial is right for you.